Cellink continues growth and expansion during an increasing global crisis

In Sweden, CELLINK, a 3D bioprinter provider and the first bioink company in the world that focuses on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications, reports an increase of 56% in net sales in their second quarter compared to the second quarter of the previous financial year.

Second quarter:

• Net sales amounted to SEK 37,241 kSEK (23,837 kSEK), corresponding to an increase of 56% (174%) compared to the second quarter of the previous financial year, of which 25% (174%) organic growth.
• Operating profit before depreciation (EBITDA) amounted to -13,755 kSEK (2,865 kSEK), corresponding to a negative margin (12.0%).
• Net income amounted to SEK -17,274 kSEK (1,340 kSEK), generating earnings per share of -0.43 SEK (0.04 SEK).

First six months:

• Net sales amounted to SEK 83,671 kSEK (43,874 kSEK), corresponding to an increase of 91% (173%) compared to the first half of the previous financial year, of which 37% (173%) organic growth.
• Operating profit before depreciation (EBITDA) amounted to -14,640 kSEK (4,466 kSEK), corresponding to a negative margin (10.2%).
• Net income amounted to SEK -22,422 kSEK (2,015 kSEK), generating earnings per share of -0.57 SEK (0.06 SEK).